UK's Mission Banks £60m To Develop DUB Inhibitors
This article was originally published in Scrip
Executive Summary
UK fund manager Neil Woodford's investment trust has joined existing investors in a £60m fundraising by Mission Therapeutics, the UK drug discovery firm working to discover drugs targeting the ubiquitin pathway. The company was set up in 2011 by the management team of kuDOS Pharmaceuticals, which was bought in 2005 by AstraZeneca after it had conducted early development of the now approved ovarian cancer drug Lynparza (olaparib), an inhibitor of poly ADP ribose polymerase (PARP). Mission's scientific founder and chief scientific officer is Professor Steve Jackson, who founded KuDOS and who continues to carry out pioneering research into DNA damage repair at Cambridge University's Gurdon Institute.
You may also be interested in...
Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors
Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.